Clinical Trial: ECOG-ACRIN EA3191

ECOG-ACRIN EA3191

Status: Open

A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features